NCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
Clinical Trials
11 trialsNCT00408005 2025-04-20
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT01085617 2025-03-30
UKALL14
University College, London
Completed
NCT03328104 2023-07-21
ENCERT
Emory University
Phase 1 Completed
NCT01094860 2020-02-11
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00406757 2017-11-13
Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma
GlaxoSmithKline
Phase 1 Completed
NCT00006020 2015-03-06
S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00003635 2013-07-18
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002970 2013-07-02
506U78 in Treating Patients With Refractory Hematologic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003837 2013-06-20
506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase NA Completed
NCT00003545 2013-02-05
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed